Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...
Pharmaceutical Technology on MSN3d
AstraZeneca’s shares rise as it addresses China investigationIn addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback